Harpharma's investment in u.S. GNC lost 1.165 billion yuan.

Guide: At present, the new crown pneumonia outbreak is still ongoing, do not rule out the possibility that GNC's future operating performance will continue to declineJune 22, HaPharma announced that its convertible preferred stock investment in GNC, a well-established U.Snutrition and health care company, has caused a loss of 1.165 billion yuan, and that the cumulative dividend receivable of 171 million yuan as of March 31, 2020 also has the risk of not being partially or completely recoverableannouncement shows that the first quarter of 2020 due to the impact of the outbreak of new crown pneumonia, GNC operating results fell sharplyAs of May 6, 2020, approximately 40% of GNC stores in the U.Sand Canada will be temporarily closed, and some stores may be closed permanently in the futureGNC's first-quarter revenue was $473 million, down 16.3 percent from a year earlier, and gross profit was $137 million, down 32.7 percent from a year earlier, financial data showedAnd in view of the current outbreak of new crown pneumonia is still ongoing, do not rule out the possibility that GNC's future operating performance will continue to declinesaid that on June 15, 2020, GNC issued a debt extension announcementGNC has reached an agreement with the relevant lender to postpone the maturity of the outstanding portion of the loan until 30 June 2020The expiration of GNC may run the risk of not being able to extend it againGNC said it would continue to look for a solution to its debtsaid that the Company's preferred investment in the U.SGNC, in accordance with the agreement and holding purposes, designated as financial assets measured at fair value and varied into other comprehensive income on the first execution date of the new financial instrumentguidelines, is listed as an investment in other equity instruments, with a total investment cost of RMB 2,062,900,923.05As of March 31, 2020, the book value was RMB897,921,771.53, and the loss of RMB1,164,979,151.52 in other consolidatedgains due to changes in fair value was RMB1,164,979,151.52, which was reflected in the periodic report; RMB 414,381.09, of which RMB6,443,782.22, RMB 130,436,493.01 and RMB34,534,105.86 of the above-mentioned Accrued Dividends may be at risk of partial or partial failure to recover in 2018, 2019 and the first quarter of 2020 .